Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 8/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346427 | 0.83 | CYP1A2 (0.57) | CA12CA1CA2CA9PHGDH | |
| SCHEMBL1346520 | 0.82 | ALDH1A1 (0.65) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL1346728 | 0.79 | MAPT (0.43) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2070112 | 0.78 | ALDH1A1 (0.56) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL7012908 | 0.78 | GAA (0.55) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL1347508 | 0.78 | MEN1 (0.46) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL31421813 | 0.75 | MAPT (0.52) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL2070576 | 0.75 | MAPT (0.52) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL602 | 0.74 | HSD11B1 (0.59) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL4022229 | 0.73 | ALDH1A1 (0.62) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167469-B1 | SULFONYL-QUINOLINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2012-08-15 | — | — | EP | disclosed |
| US-8063220-B2 | Sulfonyl-quinoline derivatives | RICHTER GEDEON NYRT. (HU) | 2011-11-22 | — | — | US | disclosed |
| EP-2167469-A1 | SULFONYL-QUINOLINE DERIVATIVES | Richter Gedeon NYRT (HU) | 2010-03-31 | — | — | EP | disclosed |
| US-20090042934-A1 | Sulfonyl-Quinoline Derivatives | RICHTER GEDEON NYRT. (HU) | 2009-02-12 | — | — | US | disclosed |
| WO-2008155588-A1 | SULFONYL-QUINOLINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042934-A1 | Sulfonyl-Quinoline Derivatives | GRM5, GRM1, GRIK5 | CA12 4337/4885CA1 1489/4885CA2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.